Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125297591 | 12529759 | 1 | I | 20160621 | 20160706 | 20160706 | EXP | AT-CIPLA LTD.-2016AT07952 | CIPLA | WOLL E, GREIL R, EISTERER W, BECHTER O, FRIDRIK MA, GRUNBERGER B ET.AL. OXALIPLATIN, IRINOTECAN AND CETUXIMAB IN ADVANCED GASTRIC CANCER. A MULTICENTER PHASE II TRIAL (GASTRIC-2) OF THE ARBEITSGEMEINSCHAFT MEDIKAMENTOSE TUMORTHERAPIE (AGMT). ANTICANCER RESEARCH. 2011;31:4439 TO 4444 | 0.00 | Y | 0.00000 | 20160706 | OT | AT | AT |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125297591 | 12529759 | 1 | PS | Irinotecan | IRINOTECAN | 1 | Intravenous (not otherwise specified) | 125 MG/M2, WAS DILUTED IN 0.9% NACL AND ADMINISTERED I.V. OVER 30 MIN, BIWEEKLY | U | U | 77219 | 125 | MG/M**2 | ||||||
| 125297591 | 12529759 | 2 | SS | OXALIPLATIN. | OXALIPLATIN | 1 | Intravenous (not otherwise specified) | 85 MG/M2, DILUTED IN 5% DEXTROSE ADMINISTERED OVER TWO HOURS, BIWEEKLY | U | U | 0 | 85 | MG/M**2 | ||||||
| 125297591 | 12529759 | 3 | SS | Cetuximab | CETUXIMAB | 1 | Intravenous (not otherwise specified) | 400 MG/M2, WAS ADMINISTERED OVER 120 MINUTES | U | U | 0 | 400 | MG/M**2 | ||||||
| 125297591 | 12529759 | 4 | SS | Cetuximab | CETUXIMAB | 1 | Intravenous (not otherwise specified) | 250 MG/M2, ADMINISTERED OVER 60 MINUTES WERE GIVEN EVERY 7 DAYS | U | U | 0 | 250 | MG/M**2 | ||||||
| 125297591 | 12529759 | 5 | C | ATROPINE. | ATROPINE | 1 | Unknown | 0.2 MG, UNK | U | U | 0 | .2 | MG |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125297591 | 12529759 | 1 | Gastric cancer |
| 125297591 | 12529759 | 2 | Gastric cancer |
| 125297591 | 12529759 | 3 | Gastric cancer |
| 125297591 | 12529759 | 5 | Prophylaxis |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 125297591 | 12529759 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125297591 | 12529759 | Disease progression |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |